---
layout: post
title: New Drug Approvals 2012 - Pt. VIII - Peginesatide (OmontysTM)
date: '2012-04-02T18:12:00.002+01:00'
author: felix
tags:
- Peptide Drugs
- Black Box Warning Drugs
- 2012 New Drugs
modified_time: '2012-04-02T18:12:36.210+01:00'
thumbnail: http://1.bp.blogspot.com/-kTQ-pdeHBfI/T3naOo69MGI/AAAAAAAAAaI/prK8a6gf-54/s72-c/omontys.jpg
blogger_id: tag:blogger.com,1999:blog-2546008714740235720.post-5855565843729615952
blogger_orig_url: http://chembl.blogspot.com/2012/04/new-drug-approvals-2012-pt-viii.html
---

<div class="separator" style="clear: both; text-align: center;">
<a href="http://1.bp.blogspot.com/-kTQ-pdeHBfI/T3naOo69MGI/AAAAAAAAAaI/prK8a6gf-54/s1600/omontys.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="320" src="http://1.bp.blogspot.com/-kTQ-pdeHBfI/T3naOo69MGI/AAAAAAAAAaI/prK8a6gf-54/s320/omontys.jpg" width="314" /></a></div>
<br />
<br />
<br />
<br />
<center face="arial"><img src="https://www.ebi.ac.uk/chembltools/autoiconlarge/5,0,1,0,1,0,1,0,1" width="400" /></center><center face="arial"><br />
</center><center face="arial"><b>ATC code</b>: <a href="http://www.whocc.no/atc_ddd_index/?code=B03XA">B03XA</a> (incomplete) </center><center face="arial"><br /></center>On March 27, the FDA approved Peginesatide for the treatment of anemia due to chronic kindney disease (CDK) in patients on dialysis. CDK is a slow but progressive loss of kidney function that can be caused by <a href="http://en.wikipedia.org/wiki/Diabetes_mellitus">diabetes mellitus</a>,&nbsp; <a href="http://en.wikipedia.org/wiki/hypertension">hypertension</a> and <a href="http://en.wikipedia.org/wiki/Glomerulonephritis">glomerulonephritis</a>, among others. One of the symptoms in the advanced stages of CDK is anemia, a decrease in the number of red blood cells and hence the <a href="http://en.wikipedia.org/wiki/Hemoglobin">hemoglobin</a> (adult hemoglobin: heterotetramer of two copies of&nbsp;<a href="http://www.uniprot.org/uniprot/P69905">P69905</a> and two copies of&nbsp;<a href="http://www.uniprot.org/uniprot/P68871">P68871</a>) content of the blood. Anemia in patients suffering from CDK is caused by reduced production of <a href="http://en.wikipedia.org/wiki/Erythropoietin">erythropoetin</a>, a hormone that regulates the levels of red blood cells and is synthesized predominantly in the cortex of the kidney.<br />
<br />
Anemia induced by CDK can be treated by supplying exogenous erythroepotin or analogs of this hormone (<i>e.g</i>. Methoxy polyethylene glycol-epoetin beta, <a href="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL1201829">CHEMBL1201829</a>). The collective term for these substances is erythropoiesis-stimulating agent (ESAs). Like endogenous erythropoetin, ESAs exert their effect through binding of the erythropeotin receptor (EpoR, Uniprot <a href="http://www.uniprot.org/uniprot/P19235">P19235</a>) and subsequent activation of the JAK2 (Uniprot <a href="http://www.uniprot.org/uniprot/O60674">O60674</a>) STAT5A (Uniprot <a href="http://www.uniprot.org/uniprot/P42229">P42229</a>) pathway, which results in increased survival of erythrocyte progenitors.<br />
<br />
Peginesatide is an ESA with no sequence homology to erythropoetin. Instead, it is composed of two synthetic 21 amino-acid peptides that are linked through a lysine branched PEG chain, as shown below.<br />
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="http://2.bp.blogspot.com/-VqfnLVkTb8c/T3nccmYeEmI/AAAAAAAAAaQ/7-CpVbpLD7Q/s1600/peginesatide.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="59" src="http://2.bp.blogspot.com/-VqfnLVkTb8c/T3nccmYeEmI/AAAAAAAAAaQ/7-CpVbpLD7Q/s320/peginesatide.png" width="320" /></a></div>
<div class="separator" style="clear: both; text-align: center;">
</div>
<div class="separator" style="clear: both; text-align: center;">
</div>
<br />
The dimeric peptide has a molecular weight of about 4.9 kDa, and the PEG chain has a molecular weight of approximately 40kDa. Peginasetide is dosed as an acetate salt. The empirical formula of the free base is C<sub>2031</sub>H<sub>3950</sub>N<sub>62</sub>O<sub>958</sub>S<sub>6</sub> and total molecular weight ~45 kDa.<br />
<br />
Peginesatide does not induce any cytochrome P450s and according to <i>in-vitro</i> protein-binding studies does not bind serum albumin or lipoproteins. The half-life of Peginesatide following intravenous administration is 25.0 ± 7.6 hours in healthy subjects and 47.9 ± 16.5 hours in dialysis patients. Clearance is 0.5 ± 0.2 mL/hr.kg and the mean volume of distribution is 34.9 ± 13.8 mL/kg. Peginesatide is mainly cleared through the urine and a study using radio-labelled Peginesatide indicates that it is not excreted unchanged.<br />
<br />
Peginesatide has a black box warning and adverse reactions include increased risk for death, myocardial infarcts, stroke, venous thromboembolism, thrombosis of vascular access and tumor progression or recurrence.<br />
<br />
An advantage of Peginesatide over other ESAs is that it can be administered at monthly intervals. Given the adverse reactions, the dosage recommendation is to individualize dosing and give the lowest dose that is sufficient to reduce the need for blood transfusions. 0.04 mg/kg is the recommended dose for probing patient response.<br />
<br />
Peginesatide was developed by <a href="http://www.affymax.com/">Affymax</a> and <a href="http://www.tpna.com/products/default.aspx">Tekeda Pharmaceuticals</a>&nbsp;and is marketed under the trade name <a href="http://omontys.com/">Omontys</a>.<br />
<br />
Full prescribing information can be found <a href="http://general.takedapharm.com/content/file/PI.pdf?applicationCode=66b0b942-e82b-46ad-886a-f4aa59f5f33c&amp;fileTypeCode=OmontysPI">here</a>.<br />
<br />